ERBB2 and cancer: Regarding peptide-based cancer vaccines, Barati et al. incorporated a human epidermal growth factor receptor 2 (HER2/neu)- derived peptide (AE36) and an adjuvant, cytosine-phosphate-guanine (CpG), in a cationic liposomal formulation composed of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP), cholesterol, and 1,2-dioleoyl-sn-glycero-3-phosphaethanolamine (DOPE) (Fig. 1A).